Harald Balló

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet · 2013 · 1.5K citations

Lymphoid Neoplasia, Rituximab Versus Chop, Oncology +10

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · Blood · 2009 · 157 citations

Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: A double-blind, randomised controlled trial

Andreas G. Franke, Patrik Gränsmark, Alexandra Agricola et al. · European Neuropsychopharmacology · 2017 · 94 citations

Cognitive Science, Psychoactive Drug, Brain Function +8

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.

Mathias Rummel, Georg Maschmeyer, Arnold Ganser et al. · Journal of Clinical Oncology · 2017 · 78 citations

Hematological Malignancy, Lymphoid Neoplasia, Surgical Oncology +14

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · Journal of Clinical Oncology · 2012 · 50 citations

Surgical Oncology, Cancer Management, Immunology +18